[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Qilu Hospital of Shandong University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":624},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,121,0,25,[9,53,78,103,127,150,172,195,215,242,267,293,313,336,361,384,410,433,457,482,506,529,552,577,600],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100644877","intraoperative-longitude-latitude-depth-localization-versus-preoperative-ct-guided-percutaneous-lung-puncture-localization-for-08-2-cm-peripheral-pulmonary-nodules-100644877",false,"NCT07675889","Intraoperative Longitude-Latitude-Depth Localization Versus Preoperative CT-Guided Percutaneous Lung Puncture Localization for 0.8-2 cm Peripheral Pulmonary Nodules","Intraoperative Longitude-Latitude-Depth Three-Dimensional Localization Versus Preoperative CT-Guided Percutaneous Lung Puncture Localization for the Treatment of 0.8-2 cm Peripheral Pulmonary Nodules: A Multicenter, Randomized, Open-Label, Non-Inferiority Clinical Trial","Inclusion Criteria:\n\n* Clinically diagnosed pulmonary nodule by non-contrast chest CT.\n* Age 18 to 80 years.\n* Expected survival time of at least 12 months.\n* Single peripheral pulmonary nodule with a diameter between 0.8 cm and 2 cm.\n* Chest CT characteristics meeting both of the following criteria:\n\n  1. Solid component proportion ≤50%.\n  2. Located subpleurally or in the outer one-third of the lung parenchyma.\n* Willing to undergo VATS-assisted sublobar resection.\n* No contraindications to pulmonary localization procedures or surgery.\n* Able to understand the study and willing to sign written informed consent.\n\nExclusion Criteria:\n\n* Use of other localization methods or other surgical procedures.\n* Concurrent participation in another clinical study.\n* Pregnancy.\n* Unwillingness or inability to cooperate with participation in this study for any reason.","ALL","18 Years","80 Years",{"count":21,"type":22},274,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to learn whether intraoperative longitude-latitude-depth three-dimensional localization (LLD localization) is non-inferior to preoperative CT-guided percutaneous lung puncture localization for identifying 0.8-2 cm peripheral pulmonary nodules in adults undergoing video-assisted thoracoscopic surgery (VATS)-assisted sublobar resection. It will also evaluate the safety and perioperative effectiveness of the two localization methods. The main questions it aims to answer are:\n\n1. Is the localization accuracy rate of LLD localization non-inferior to that of CT-guided percutaneous lung puncture localization?\n2. Does LLD localization improve perioperative outcomes, including localization time, postoperative recovery, pain, quality of life, and perioperative complication rates?\n\nResearchers will compare LLD localization with CT-guided percutaneous lung puncture localization to determine whether LLD localization provides comparable localization accuracy while reducing procedure-related complications and improving perioperative outcomes.\n\nParticipants will:\n\n1. Be randomly assigned in a 1:1 ratio to either the LLD localization group or the CT-guided percutaneous lung puncture localization group.\n2. Undergo pulmonary nodule localization using the assigned localization method.\n3. Receive VATS-assisted sublobar resection following localization.\n4. Be assessed for localization accuracy, perioperative complications, localization time, postoperative chest drainage tube removal time, oxygenation index, postoperative hospital stay, pain scores, and quality-of-life outcomes.\n5. Complete follow-up assessments at 1, 3, and 6 months after surgery.",[28,29,30],"Pulmonary Nodule, Solitary","Peripheral Pulmonary Nodules","Pulmonary Nodules",[32,33,34,35,36,37,38,39],"Peripheral Pulmonary Nodule","Pulmonary Nodule Localization","Longitude-Latitude-Depth Localization","CT-Guided Percutaneous Localization","Video-Assisted Thoracoscopic Surgery","Sublobar Resection","Randomized Controlled Trial","Non-Inferiority Trial","NOT_YET_RECRUITING","2026-06-23",{"date":43,"type":44},"2026-06-30","ACTUAL",{"date":46,"type":22},"2026-07-01",{"date":48,"type":22},"2028-07-01",{"name":50,"class":51},"Qilu Hospital of Shandong University","OTHER",4,{"id":54,"slug":55,"hasResults":12,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100641112","mcg-for-non-obstructive-myocardial-ischemia-100641112","NCT07657546","MCG for Non-Obstructive Myocardial Ischemia","Magnetocardiography in the Identification of Non-Obstructive Myocardial Ischemia of Patients With Acute Chest Pain","Inclusion Criteria:\n\n* Age 18 years or older;\n* Patients with symptoms of myocardial ischemia such as angina pectoris, who have CAG showing \\\u003C70% stenosis at the most severe site or CTA showing non-severe stenosis\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Patients with absolute or relative contraindications to CFR-loaded myocardial perfusion, including acute myocardial infarction within 48 hours, significant left main coronary artery stenosis, bronchial asthma, and adenosine injection allergy;\n* Patients with Non-ischemic dilated cardiomyopathy, or hypertrophic cardiomyopathy, or moderate or severe valvular disease;\n* Patients with Hemodynamic instability (systolic blood pressure\\\u003C90 mmHg, or who requires vasoactive drugs), or patients with tachyarrhythmia,\n\n  #degree atrioventricular block and above that have not returned to normal;\n* Patients who have severe renal abnormality with eGFR \\\u003C30 ml\u002Fmin, or patients who are on dialysis;\n* Patients with malignant tumors with predicted survival of less than 1 year;\n* Pregnant or breastfeeding women;\n* Patients who are unable to enter the MCG device, who are unable to perform MCG examination due to interference from metal implants or other reasons, or who are deemed by the investigators to be unsuitable for enrollment.",{"count":61,"type":22},3786,"OBSERVATIONAL","The aim of this prospective study is to identify Non-Obstructive Myocardial Ischemia of patients who have acute chest pain using Magnetocardiography.",[65],"Myocardial Ischemia",[67],"Ischemia with No Obstructive Coronary Arteries","RECRUITING","2026-06-21",{"date":71,"type":44},"2026-06-24",{"date":73,"type":44},"2025-04-15",{"date":75,"type":22},"2026-08-30",{"name":50,"class":51},1,{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":12,"sex":85,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":88,"studyType":62,"phases":4,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":4},"100642190","tte-study-of-ql1706-in-recurrentmetastatic-cervical-cancer-100642190","NCT07652983","TTE Study of QL1706 in Recurrent\u002FMetastatic Cervical Cancer","Real-World Effectiveness and Safety of Iparomlimab and Tuvonralimab in Recurrent or Metastatic Cervical Cancer: A Target Trial Emulation Study","Inclusion Criteria:\n\n* Participants voluntarily agree to participate in the study and provide written informed consent.\n* Age ≥18 years at the time of signing the informed consent form.\n* Histologically confirmed recurrent or metastatic cervical cancer (FIGO 2018 stage IVB), including squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.\n* Disease progression or treatment failure following prior platinum-based chemotherapy.\n* At least one measurable target lesion according to RECIST version 1.1, as assessed by CT or MRI.\n* Estimated life expectancy of at least 3 months.\n* Considered suitable by the investigator for antitumor treatment with Iparomlimab and Tuvonralimab (QL1706), either as monotherapy or in combination with other therapies, and with a planned treatment regimen including QL1706.\n\nExclusion Criteria:\n\n* Histological subtypes including sarcoma, small-cell carcinoma with neuroendocrine differentiation, or other non-epithelial malignancies.\n* History of severe hypersensitivity reaction (Grade ≥3) to Iparomlimab and Tuvonralimab (QL1706) and\u002For any of its excipients.\n* Known additional malignancy that has progressed or required active treatment within the past 3 years.\n* Active autoimmune disease requiring systemic treatment within the past 2 years (e.g., disease-modifying agents, corticosteroids, or immunosuppressive therapy); history of non-infectious pneumonitis requiring steroid treatment, or current pneumonitis.\n* Active infection requiring systemic therapy.\n* Any other medical condition, laboratory abnormality, or circumstance that, in the investigator's judgment, would make the participant unsuitable for participation in this study.","FEMALE",{"count":87,"type":22},280,"2 Years","The goal of this observational study is to evaluate the effectiveness and safety of Iparomlimab and Tuvonralimab (QL1706)-based therapy in patients with recurrent or metastatic cervical cancer who have experienced disease progression after platinum-based treatment.\n\nThe main questions it aims to answer are:\n\n* Does QL1706-based therapy improve clinical outcomes compared with investigator-selected chemotherapy in patients with recurrent or metastatic cervical cancer?\n* Does the addition of bevacizumab further improve treatment effectiveness?\n* Which patient subgroups are most likely to benefit from QL1706-based therapy? Participants receiving QL1706-based therapy or investigator-selected chemotherapy as part of routine clinical practice will be followed through real-world clinical data collection. Using a target trial emulation framework, the study will compare treatment effectiveness and safety between groups. Clinical characteristics, treatment outcomes, and adverse events will be collected for analysis. In addition, artificial intelligence-based models and multi-omics analyses will be used to identify predictive biomarkers and explore potential mechanisms of treatment response and resistance.",[91],"Recurrent or Metastatic Cervical Cancer",[93,94],"Recurrent or metastatic cervical cancer","Iparomlimab and Tuvonralimab","2026-06-11",{"date":97,"type":44},"2026-06-17",{"date":99,"type":22},"2026-06-15",{"date":101,"type":22},"2029-12-31",{"name":50,"class":51},{"id":104,"slug":105,"hasResults":12,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":23,"phases":113,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":121,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":77},"100599800","phase-2-tislelizumab-combined-with-anlotinib-and-nab-paclitaxel-in-iii-resectable-non-small-cell-lung-cancer--a-prospective-single-arm-phase-ii-study-100599800","NCT07089199","Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study","TitAN","Inclusion Criteria:\n\n1. Age 18-75 years old, gender is not limited;\n2. Histologically confirmed Stage III non-small cell lung cancer (AJCC Stage 8th edition)\n3. The tumor is resectable after assessment by the attending surgeon\n4. EGFR\u002FALK mutation negative or unknown (unknown only for squamous non-small cell lung cancer)\n5. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n6. No previous treatment received\n7. At least 1 measurable lesion as defined by RECIST v1.1\n8. Be able to provide the Informed Consent Form (ICF), and be able to understand and agree to abide by the research requirements and assessment schedule\n9. Good organ function; • Patients have not received blood transfusion or growth factor support therapy ≤ 14 days prior to sample collection during the screening period and: Absolute neutral cell count (ANC) ≥1.5 x 109\u002FL Platelet ≥100 x 109\u002FL Hemoglobin ≥90 g\u002FL • Calculated creatinine clearance (CrCl) (Cockcroft-Gault formula) creatinine clearance ≥ 45 mL\u002Fmin Serum total bilirubin ≤1.5 × upper limit of normal (ULN) (patients with Gilbert\\'s syndrome must have total bilirubin \\< 3 × ULN) AST and ALT≤ 2.5 x ULN Patients who did not receive anticoagulant therapy: International standardized ratio or activated partial thromboplastin time ≤ 1.5 × ULN\n10. Women of childbearing age must take a serum pregnancy test within 3 days before the first medication, and the result is negative. Female subjects of reproductive age and male subjects whose partners are women of reproductive age must agree to use highly effective methods of contraception during the study period and for 120 days after the last dose of the study drug\n\nExclusion Criteria:\n\n1. A history of received treatment for current lung cancer, including radiotherapy and all systemic antitumor agents, including chemotherapy, immunotherapy, targeted therapy or antiangiogenic therapy.\n2. Patients with known EGFR gene mutation, ALK rearrangement, ROS-1 fusion, RET fusion, HER-2 mutation, MET mutation, but if patients with squamous non-small cell lung cancer, the EGFR mutation status and ALK mutation status are unknown, it is not required to conduct tests during screening\n3. There are multiple factors influencing patients taking oral medication (such as inability to swallow, chronic diarrhea, intestinal obstruction)\n4. Allergy to any study drug (Tislelizumab, Anlotinib, albumin-bound Paclitaxel) or excipients.\n5. Imaging shows that the tumor has invaded important blood vessels or the investigator judges that the tumor invasion of important blood vessels during treatment is likely to cause fatal bleeding.\n6. Clinically significant hemoptysis (more than 50 ml per day) within 3 months before the study, or clinically significant bleeding symptoms or obvious bleeding tendency (such as gastrointestinal bleeding, gastric ulcer bleeding, gastrointestinal bleeding, hemorrhagic gastric ulcer, fecal occult blood ++ and above baseline, or suffering from vasculitis, etc.).\n7. Vaccination with attenuated live vaccines within 4 weeks before the first dose or planned vaccination during the study period.\n8. Patients who are expected to be unable to tolerate surgery, such as those with cardiopulmonary insufficiency.\n9. Occurrence of or concurrent other malignancies within the past 5 years, except for cured cervical carcinoma in situ, non-melanoma skin cancer, and superficial bladder tumors \\[Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor invading the basement membrane)\\].\n10. Patients with active viral hepatitis requiring treatment as determined by the investigator.\n11. Active autoimmune diseases requiring systemic treatment, or long-term use of high doses of steroids or other immunomodulators, which the investigator assesses as affecting the study treatment.\n12. Unhealed surgical incisions before the start of study treatment (small biopsy incisions can be included).\n13. Active hepatitis B\u002FC infection and human immunodeficiency virus (HIV) infection.\n14. Arterial or venous thrombotic events within 6 months (such as cerebrovascular accident, deep vein thrombosis, pulmonary embolism, etc.) or severe cardiovascular diseases: myocardial ischemia or myocardial infarction above grade II, uncontrolled arrhythmias; heart failure above grade III-IV according to NYHA standards, or left ventricular ejection fraction (LVEF) \\\u003C 50% as indicated by echocardiography.\n15. Interstitial lung disease, uncontrolled systemic medical history, including diabetes, hypertension, acute lung disease, etc.\n16. Active bleeding or coagulation dysfunction (INR \\> 2.0, PT \\> 16s), bleeding tendency or receiving thrombolytic, anticoagulant, antiplatelet therapy; any major surgery requiring general anesthesia within ≤ 28 days before the first dose.\n17. Underlying medical conditions or alcohol\u002Fdrug abuse that are unfavorable for the administration of study drugs, may affect the interpretation of results, or pose a high risk of treatment complications.","75 Years",{"count":112,"type":22},34,[114],"PHASE2","This study is a single-arm prospective clinical trial. The primary objective of the study is to explore the efficacy and safety of preoperative neoadjuvant therapy with Tislelizumab combined with Anlotinib and Nab-Paclitaxel in resectable stage III non-small cell lung cancer.Finally, it provides new evidence-based medical evidence for the perioperative treatment of non-small cell lung cancer.",[117,118,119,120],"NSCLC","Tislelizumab","Anlotinib","Nab-paclitaxel",{"date":99,"type":44},{"date":123,"type":44},"2025-07-25",{"date":125,"type":22},"2028-07-10",{"name":50,"class":51},{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":135,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":23,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":4},"100641690","online-booster-training-system-for-improving-cpr-quality-100641690","NCT07649343","Online Booster Training System for Improving CPR Quality","Improving CPR Quality With Online Booster Training System in Medical Students: A Randomized Controlled Trial","OBS-CPR","Inclusion Criteria:\n\n* Aged ≥ 18 years\n* no CPR training within the past 3 years\n* Full attendance and completion of the initial offline CPR course\n* Voluntary participation and signed informed consent\n* Availability of smart phones, tablets or computers for online training and follow-up\n\nExclusion Criteria:\n\n* Physical limitations preventing high-quality chest compression (e.g., severe carpal tunnel syndrome, spinal diseases, etc.)\n* Prior CPR learning experience or potential access to additional spontaneous CPR booster training after initial training\n* Unavailability to complete follow-up assessments within the study period for any reason.",true,{"count":137,"type":22},210,[25],"Improving CPR Quality with Online Booster Training System in Medical Students: A Randomized Controlled Trial\n\n1. Objective To explore the effect of the online booster training system on cardiopulmonary resuscitation (CPR) skill retention among adult CPR learners.\n2. Participants Medical university students, who have received the standardized offline AHA BLS course.\n\n   Inclusion Criteria\n   * Aged ≥ 18 years\n   * no CPR training within the past 3 years\n   * Full attendance and completion of the initial offline CPR course\n   * Voluntary participation and signed informed consent\n   * Availability of smart phones, tablets or computers for online training and follow-up Exclusion Criteria\n   * Physical limitations preventing high-quality chest compression (e.g., severe carpal tunnel syndrome, spinal diseases, etc.)\n   * Prior CPR learning experience or potential access to additional spontaneous CPR booster training after initial training.\n   * Unavailability to complete follow-up assessments within the study period for any reason.\n3. Randomization Participants will be randomly allocated (1:1) to either of groups using the online system, with an online random number generator (www.randomizer.org). The numbers were randomly assigned to consented participants by a person, who is not a member of the research team.\n\n   Blinding: Outcome assessors, offline training instructors and statistical analysts are blinded. Due to the nature of the intervention, participants are not blinded.\n4. Interventions Intervention group (Online Booster Training Group) Requirements: Within 3 months after initial training, participants should complete full online training session at least once per month.\n\n   Platform: Qilu Online Booster Training System for Adult Cardiopulmonary Resuscitation.\n\n   Contents: Teaching review (video lectures); practice assessment.\n\n   Control group (No Booster Training Group) No booster training of any form was provided. Participants only returned for outcome assessment at the designed time.\n5. Outcomes 5.1 Primary Outcome Excellent CPR, which was defined as at least 90% guideline-compliance for depth, rate and recoil of chest compression.\n\n   5.2 Secondary Outcome (i) compression depth (mm), assessed with the certified CPR manikins (ii) compression rate (per minute), assessed with the certified CPR manikins (iii) Percentage of compression depth \\> 50 mm (iv) Percentage of CC (chest compression) with rate of 100-120\u002Fmin (v) Percentage of CC with complete recoil. (vi) The pass rate of theoretical test\n6. Sample Size Calculation The sample size was estimated based on the primary outcome measure. A previous study showed that the proportion of \"excellent CPR\" without booster training is 88%. We expected to detect a 10% difference in the proportion of excellent CPR between groups. Based on these assumptions, an alpha of 0.05 and a power of 0.8, assuming a dropout of 5%, we will aim to include 105 participants per group, that is, a total of 210 participants.\n7. Statistical Analysis variables will be assessed for normal distribution and reported as means (SD) or medians (IQR), whichever is appropriate. Continuous data will be compared using a Student's t-test or Mann-Whitney U test, whichever is appropriate. Categorical variables will be reported as numbers (%) and compared using χ2 or Fisher's exact tests, whichever is appropriate. All baseline variables and outcome data variables will also be compared between the two study groups using the abovementioned tests. In case of confounding variables, we will correct comparisons on the outcome measures between the study groups for these confounders using analysis of covariance. A p-value of \\\u003C0.05 will be considered statistically significant. Analyses will be performed using SPSS V.25",[141],"CPR Skills","2026-06-09",{"date":144,"type":44},"2026-06-16",{"date":146,"type":22},"2026-06-10",{"date":148,"type":22},"2027-06-10",{"name":50,"class":51},{"id":151,"slug":152,"hasResults":12,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":110,"enrollmentInfo":157,"targetDuration":4,"studyType":23,"phases":159,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":77},"100643800","comparison-of-double-tract-and-tubular-gastric-anastomosis-in-proximal-gastric-cancer-100643800","NCT07635836","Comparison of Double-tract and Tubular Gastric Anastomosis in Proximal Gastric Cancer","Comparison of Gastroesophageal Reflux and Quality of Life Between Double-tract and Tubular Gastric Anastomosis in Proximal Gastric Cancer Patients","Inclusion Criteria:\n\n* Pathologically confirmed gastric adenocarcinoma by biopsy\n* Carcinoma of the upper gastric body or Siewert type II\u002FIII adenocarcinoma of the esophagogastric junction (AEG), with a clinical stage of cT1-3N0-1M0\n* Age 18-75 years, with a performance status (PS) score of 0-2\n* Candidates for planned surgical resection, eligible for either double-tract reconstruction or tubular gastric anastomosis based on preoperative assessment\n* No severe dysfunction of vital organs (liver, kidney, heart, lung, or brain), and no severe infection or uncontrolled chronic diseases\n\nExclusion Criteria:\n\n* Presence of other malignant tumors or severe chronic diseases (e.g., severe diabetes mellitus, chronic kidney disease, decompensated cirrhosis, etc.)\n* Preoperative endoscopic diagnosis of Barrett's esophagus\n* Severe preoperative malnutrition (albumin \\\u003C30 g\u002FL, prealbumin \\\u003C150 mg\u002FL)\n* History of prior upper abdominal surgery, gastrointestinal malformation, or psychiatric disorders\n* Preoperative diagnosis of obstructive motor disorders of the cardia (including achalasia spectrum disorders)\n* Inability to cooperate with or complete the required postoperative examinations",{"count":158,"type":22},52,[25],"This study includes patients diagnosed with proximal gastric cancer (Siewert type II\u002FIII, cT1-3N0-1M0) across six tertiary hospitals, who underwent either double-tract reconstruction (DTR) or tubular gastric anastomosis (TGA). Participants were divided into two groups based on the surgical procedure. We conducted a comparative analysis of postoperative outcomes by evaluating electronic medical records, postoperative gastroscopy, 24-hour esophageal pH monitoring, and relevant rating scales.",[162,163,164],"Gastric Cancer (GC)","Double-tract Reconstruction","Tubular Gastric Anastomosis","2026-06-03",{"date":142,"type":44},{"date":168,"type":44},"2026-05-01",{"date":170,"type":22},"2027-10-01",{"name":50,"class":51},{"id":173,"slug":174,"hasResults":12,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":12,"sex":85,"minAge":179,"maxAge":19,"enrollmentInfo":180,"targetDuration":4,"studyType":23,"phases":182,"briefSummary":183,"conditions":184,"keywords":187,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":191,"startDateStruct":192,"completionDateStruct":193,"leadSponsor":194,"locationsCount":77},"100643811","a-novel-wearable-transcutaneous-tibial-nerve-stimulation-ttns-device-in-the-treatment-of-patients-with-overactive-bladder-oab-and-nocturia-100643811","NCT07635251","A Novel Wearable Transcutaneous Tibial Nerve Stimulation (TTNS) Device in the Treatment of Patients With Overactive Bladder (OAB) and Nocturia","A Novel Wearable Transcutaneous Tibial Nerve Stimulation (TTNS) Device Combined With Behavioral Therapy (BT) Versus Behavioral Therapy in the Treatment of Patients With Overactive Bladder (OAB) and Nocturia: a Prospective, Randomized Controlled Study","Inclusion Criteria:\n\n1. age ≥20 years old, ≤80 years old, female;\n2. patients with overactive bladder (OAB) symptoms for more than 8 weeks; The inclusion criteria were as follows: voiding frequency ≥8 times in 24 hours, urgency attack ≥1 time in 24 hours, nocturnal voiding ≥2 times (OABSS score ≥6 points), and nocturnal polyuria index (NPi) ≤0.33.\n3. the patient's physical condition is stable and can be treated at home;\n4. All participants volunteered to participate in the study and provided written informed consent before the study began.\n\nExclusion Criteria:\n\n1. Residual urine volume ≥100 mL;\n2. difficulty walking;\n3. urethral stricture;\n4. bladder stones;\n5. bladder cancer;\n6. urinary tract infection;\n7. pregnant, lactating women, women of childbearing age who plan to become pregnant during the study or who do not use safe contraception;\n8. pelvic organ prolapse;\n9. neuropsychiatric disorders (including cerebrovascular diseases) associated with neurogenic bladder;\n10. taking medications for urinary system diseases within 2 weeks before enrollment;\n11. patients with mental and cognitive impairment who are unable to cooperate with treatment;\n12. other conditions considered by the investigator to be inappropriate for study participation.","20 Years",{"count":181,"type":22},80,[25],"Overactive bladder (OAB) is a syndrome with urgency as the main symptom, usually accompanied by frequent urination, nocturia, and sometimes urge urinary incontinence. Globally, the prevalence of OAB in the general population has been reported to be about 20%. Nocturia was defined as the patient waking up at least once during the night to urinate. Among lower urinary tract symptoms, nocturia can significantly affect daily life and quality of life. Reported causes of nocturia include nocturnal polyuria, sleep disorders, circadian rhythm disruption (e.g., circadian rhythm sleep disorders), and reduced bladder capacity. Because overactive bladder (OAB) may be associated with reduced bladder capacity, anticholinergic agents are used as standard therapy in the management of nocturia associated with OAB. However, anticholinergic medications are associated with poor adherence, such as inadequate efficacy and adverse effects (e.g., dry mouth, constipation, and cognitive impairment). Therefore, it is imperative to find alternative therapies for anticholinergic drugs.\n\nPrevious studies have shown that transcutaneous tibial nerve stimulation (TNS) can also significantly improve lower urinary tract symptoms, such as frequency, urgency, incontinence, and nocturia, and is also one of the options for the treatment of OAB. A previous study also demonstrated its improvement in sleep quality in women with nocturia. However, the efficacy of tibial nerve stimulation in the treatment of active bladder with nocturia is still a blank, and further studies are needed.",[185,186],"Overactive Bladder (OAB)","Nocturia",[188,189,190],"transcutaneous tibial nerve stimulation","overactive bladder","nocturia",{"date":142,"type":44},{"date":146,"type":22},{"date":148,"type":22},{"name":50,"class":51},{"id":196,"slug":197,"hasResults":12,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":202,"targetDuration":4,"studyType":23,"phases":204,"briefSummary":205,"conditions":206,"keywords":207,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":210,"startDateStruct":211,"completionDateStruct":212,"leadSponsor":214,"locationsCount":77},"100643484","efficacy-of-probiotics-for-oab-patients-with-anxiety-100643484","NCT07635212","Efficacy of Probiotics for OAB Patients With Anxiety","Evaluating the Efficacy of Probiotics as an Adjunct to Behavioral Therapy in Patients With Overactive Bladder (OAB) and Anxiety Symptoms: A Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n1. Aged between 18 and 80 years old (inclusive).\n2. Able to understand study-related instructions and independently complete the required questionnaires.\n3. Able to provide written informed consent and willing to comply with all study requirements, including completing diaries\u002Fquestionnaires and refraining from taking any other probiotic or prebiotic supplements during the 3-month study period.\n4. Meet the diagnostic criteria for Overactive Bladder (OAB) as defined by the International Continence Society (ICS) (urgency as the core symptom, with or without urgency urinary incontinence, frequency, and nocturia); have an Overactive Bladder Symptom Score (OABSS) ≥ 6; and have a daytime voiding frequency of ≥ 8 times.\n5. Have a preliminary diagnosis of \"Generalized Anxiety Disorder\" or \"Anxiety state\" assessed by a psychiatrist or trained investigator according to DSM-5 or ICD-10 criteria, or have a Generalized Anxiety Disorder-7 (GAD-7) scale score ≥ 5.\n6. If previously using any over-the-counter medications or other products for anxiety relief (e.g., magnesium, melatonin, anticholinergic drugs) or receiving psychotherapy, these must have been discontinued for at least 4 weeks prior to randomization and must remain completely discontinued throughout the entire study period.\n\nExclusion Criteria:\n\n1. Presence of organic diseases of the urinary system (e.g., urinary tract obstruction, tumors, stones, acute infection, interstitial cystitis, stress urinary incontinence).\n2. Neurogenic bladder caused by neurological diseases or a history of pelvic surgery.\n3. Use of antibiotics, probiotics, or prebiotics within the past 1 month prior to screening.\n4. Any adjustment to medications used for treating OAB or anxiety within the past 2 weeks prior to screening.\n5. Pregnant or lactating women, or individuals with a known allergy to any components of the study preparation.\n6. Suffering from other severe psychiatric\u002Fpsychological disorders or severe systemic diseases (e.g., uncontrolled diabetes mellitus, severe obesity).",{"count":203,"type":22},218,[25],"The goal of this clinical trial is to learn if probiotics can help improve symptoms in adults with overactive bladder (OAB) and anxiety. The main questions it aims to answer are:\n\n1. Does taking probiotics lower the number of times participants need to urinate in a 24-hour period?\n2. Does taking probiotics lower participants' anxiety levels?\n\nResearchers will compare probiotics to a placebo (a look-alike powder that contains no active bacteria) to see if the probiotics work better to treat OAB and anxiety when both groups also use standard behavioral therapy (like bladder training).\n\nParticipants will:\n\n1. Take probiotics or a placebo twice a day for 12 weeks.\n2. Learn and practice bladder training using a manual and educational videos.\n3. Keep a 3-day diary of when they urinate and what they drink at the beginning, middle, and end of the study.\n4. Answer survey questions about their anxiety and quality of life during clinic visits.\n5. Provide urine samples for routine checkups to ensure they do not have infections.",[185],[208,209,189],"probiotics","OAB",{"date":142,"type":44},{"date":46,"type":22},{"date":213,"type":22},"2028-12-31",{"name":50,"class":51},{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":110,"enrollmentInfo":223,"targetDuration":4,"studyType":23,"phases":225,"briefSummary":226,"conditions":227,"keywords":229,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":241},"100570728","target-directed-management-of-cerebral-oxygenation-in-patients-after-receiving-ecpr-100570728","NCT06711016","Target-directed Management of Cerebral Oxygenation in Patients After Receiving ECPR","Efficacy and Safety of Target-directed Management of Cerebral Oxygenation in Patients Undergoing Extracorporeal Cardiopulmonary Resuscitation: A Multicenter, Pragmatic, Randomized, Controlled Clinical Trial","TDMCO-ECPR","Inclusion criteria:\n\n1. 18-75 years old\n2. Witnessed in-hospital or out-of-hospital cardiac arrest\n3. Patients who did not achieve return of spontaneous circulation (ROSC) after 15 minutes of conventional cardiopulmonary resuscitation (CPR), or whose ROSC cannot be maintained, and who received ECPR\n4. Time from cardiac arrest to initiation of CPR \\\u003C 10 minutes\n5. The cause of cardiac arrest is expected to be reversible (e.g., hypothermia, acute myocardial infarction\u002Fmyocardial ischemia, malignant arrhythmia, pulmonary embolism, electrolyte abnormalities, hypoxia, anaphylactic shock, hemorrhage\u002Fhypovolemia, drug poisoning, electric shock, etc.)\n\nExclusion criteria:\n\n1. Aortic dissection\n2. Participants with active gastrointestinal bleeding or other conditions with contraindications to anticoagulation\n3. Pregnancy\n4. Severe trauma\n5. Cerebral Performance Category (CPC) score \\> 2 before cardiac arrest, or acute cerebrovascular disease (e.g., suspected or confirmed acute stroke, subarachnoid hemorrhage, etc.)\n6. Terminal diseases, such as malignant tumors, end-stage liver and kidney diseases, severe heart failure (NYHA class III or IV), severe COPD (GOLD class III or IV), etc.\n7. Transfer time from cardiac arrest to extracorporeal membrane oxygenation (ECMO) \\> 90 minutes\n8. Previous history of bilateral femoral artery bypass grafting or artificial vascular replacement, unsuitable for ECMO catheterization",{"count":224,"type":22},654,[25],"Neurological injury remains an important cause of morbidity and mortality in patients with ECPR. At present, the results of three prospective randomized controlled studies on ECPR are inconsistent, and it is inconclusive whether ECPR can improve the neurological outcomes of patients with refractory cardiac arrest. Several study found that extracorporeal membrane oxygenation nonsurvivors can lead toacute brain injury.Further research with a systematic neurologic monitoring is necessary to define the timing of acute brain injury in patients with extracorporeal membrane oxygenation.Moreover, brain injury that occurs during extracorporeal membrane oxygenation therapy is not easy to detect in time because of the use of analgesics, sedatives, and muscle relaxants. Surprisingly, little attention has been paid to the role of cerebral perfusion and oxygenation. Moreover,the features of cerebrovascular pathophysiology and optimal management strategies are still vague.\n\nTherefore multimodal neuromonitoring may be a valuable tool for detecting brain injury in patients with extracorporeal membrane oxygenation and providing early intervention guidance.\n\nMultimodal neuromonitoring, integrating tools such as near-infrared spectroscopy (NIRS), transcranial Doppler, and continuous electroencephalography, may enable early detection of brain injury and guide targeted interventions.\n\nHypothesis: Multimodal neuromonitoring combined with a standard care management will increase the proportion of patients achieving survival with favorable neurological outcome (Cerebral Performance Category \\[CPC\\] 1-2) at 30 days compared with standard care without protocolized neuromonitoring.\n\nPrimary Objective: To test whether a multimodal neuromonitoring strategy improves 30-day survival with favorable neurological outcome (CPC 1-2) in adult patients with refractory cardiac arrest treated with ECPR.",[228],"Cardiac Arrest",[230,231,232,233],"Multimodality Neuromonitoring","ECPR","Out-of-hospital Caridac arrest","In-Hospital Cardiac Arrest",{"date":235,"type":44},"2026-06-08",{"date":237,"type":44},"2025-04-22",{"date":239,"type":22},"2028-07-30",{"name":50,"class":51},2,{"id":243,"slug":244,"hasResults":12,"nctId":245,"briefTitle":246,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":23,"phases":251,"briefSummary":252,"conditions":253,"keywords":255,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":77},"100580259","colistin-methanesulfonate-sodium-inhalation-for-prophylaxis-of-ventilator-associated-pneumonia-civap-a-prospective-multicentre-double-blind-randomized-placebo-controlled-trial-100580259","NCT06834971","Colistin Methanesulfonate Sodium Inhalation for Prophylaxis of Ventilator-Associated Pneumonia (CIVAP): A Prospective, Multicentre, Double-Blind, Randomized, Placebo-Controlled Trial","CIVAP","Participants will be enrolled if they meet the following criteria:\n\n1. Age ≥18 years;\n2. Mechanical ventilation for more than two consecutive days (48 hours);\n3. Patient has high-risk factors for multidrug-resistant bacterial infections, which meet any of the following criteria:\n\n(1)History of antibiotic exposure within 30 days; (2)Hospitalization time\\>5 days (120 hours); (3)Septic shock; (4) ARDS; (5)Accept renal replacement therapy; (6)Previous colonization of multidrug-resistant bacteria; 4. Informed consent of the patient or a proxy was written.\n\nParticipants will be excluded in case of:\n\n1. Suspected or confirmed VAP at the inclusion day;\n2. Patient ventilated through an endotracheal tube for more than four consecutive days (96 hours);\n3. Expected that endotracheal intubation will be removed within the next 24 hours;\n4. Tracheostomy;\n5. Allergy to CMS;\n6. Patients has polymyxins medication history within 7 days or clinical indication for systemic CMS therapy at the inclusion day;\n7. Chronic kidney failure with baseline glomerular filtration ≤30 mL\u002Fmin or Stage 3 classification AKI (KDIGO) (excluding patients undergoing renal replacement therapy);\n8. Expected survival time not exceeding 48 hours;\n9. Pregnancy or breastfeeding period;\n10. Patients previously included in this study or are using any inhaled antibiotics or are participating in other clinical studies within 30 days.",{"count":250,"type":22},508,[25],"Previous studies have identified Acinetobacter baumannii (AB), Pseudomonas aeruginosa (PA), and Klebsiella pneumoniae (KP) as the predominant pathogens responsible for ventilator-associated pneumonia (VAP). The challenge of drug resistance, especially against carbapenem is intensifying, with variations noted across different regions. Multidrug-resistant organisms associated VAP (MDR-VAP) are increasing in frequency and are associated with significant morbidity, mortality, therefore imposes a heavy burden on the healthcare system. Colistin methanesulfonate sodium (CMS) has shown effectiveness against gram-negative bacteria, including carbapenem-resistant organisms (CRO) such as carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Pseudomonas aeruginosa (CRPA), and carbapenem-resistant Klebsiella pneumoniae (CRKP). This trial aims to evaluate the efficacy of a 3-day course of inhaled CMS in lowering the incidence of VAP among patients undergoing invasive mechanical ventilation for at least two days and at high risk of MDR-VAP.",[254],"Ventilator-Associated Pneumonia (VAP)",[256,257,258],"colistin","prevention","nebulization","2026-05-16",{"date":261,"type":44},"2026-05-19",{"date":263,"type":44},"2025-07-15",{"date":265,"type":22},"2026-12",{"name":50,"class":51},{"id":268,"slug":269,"hasResults":12,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":23,"phases":276,"briefSummary":277,"conditions":278,"keywords":280,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":77},"100631010","prophylactic-ps-placement-to-prevent-pancreatitis-after-endoscopic-transpapillary-gpc-for-cholelithiasis-with-concomitant-choledocholithiasis-100631010","NCT07495111","Prophylactic PS Placement to Prevent Pancreatitis After Endoscopic Transpapillary GPC for Cholelithiasis With Concomitant Choledocholithiasis","Prophylactic Pancreatic Stent Placement to Prevent Pancreatitis After Endoscopic Transpapillary Gallbladder-preserving Cholecystolithotomy for Cholelithiasis With Concomitant Choledocholithiasis","Inclusion Criteria:\n\n1. Patients aged 18 years or older;\n2. Patients with gallbladder stones and common bile duct (CBD) stones confirmed by ultrasound and\u002For MRCP or other imaging modalities (CT\u002FMRI);\n3. Patients with every gallbladder stone ≤1 cm in diameter or sludge-like stones;\n4. Patients without a history of gastrointestinal reconstruction surgery,cholecystectomy or previous biliary surgery, includes ERCP;\n5. The morphology and size of the gallbladder are essentially normal and the thickness of the gallbladder wall is ≤3 mm;\n6. Patients with at least one of the following high-risk factors for post-ERCP pancreatitis (PEP): suspected sphincter of Oddi dysfunction (SOD), female sex, history of pancreatitis, difficult cannulation (defined as ≥5 cannulation attempts or ≥5 minutes of cannulation time), pancreatic duct contrast injection, age \\\u003C35 years, non-dilated extrahepatic bile duct, no history of chronic pancreatitis, normal serum bilirubin, precut sphincterotomy, biliary balloon dilation, incomplete bile duct stone clearance, or intraductal ultrasound ;\n7. Patients who voluntarily provide signed informed consent.\n\nExclusion Criteria:\n\n1. Patients with any of the following diagnoses: chronic atrophic cholecystitis, porcelain gallbladder, suspected gallbladder malignancy, or Mirizzi syndrome;\n2. Patients with ectopic duodenal papilla or congenital pancreaticobiliary malformations;\n3. Patients unfit for ERCP endoscopic treatment due to severe systemic diseases;\n4. Patients with severe coagulation dysfunction (defined as an International Normalized Ratio \\[INR\\] \\>1.5) or significant thrombocytopenia (platelet count \\\u003C50×10⁹\u002FL);\n5. Pregnant women;\n6. Patients with guidewire entry into the pancreatic duct ≥3 times during the procedure;\n7. Patients with allergies to aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs);\n8. Patients with congenital or acquired absence of the rectum;\n9. Patients with severe acute pancreatitis",{"count":275,"type":22},88,[25],"In this multicenter, randomized trial, patients with cholelithiasis with concomitant choledocholithiasis based on inclusion and exclusion criteria will be randomly assigned to receive rectal indomethacin alone or the combination of indomethacin plus a prophylactic pancreatic stent after endoscopic transpapillary gallbladder-preserving cholecystolithotomy.Clinical data and patient-reported outcomes are regularly collected at baseline and during follow-up periods. The study aims to analyze the impact of pancreatic duct stent implantation on the incidence of post-ERCP pancreatitis in gallstone patients treated with ERCP-GPC by comparing the efficacy differences between the experimental and control groups. Additionally, the study investigate the effects of pancreatic duct stent placement post-ERCP on other postoperative complications, conduct a comparative analysis of the economic benefits of placing versus not placing pancreatic duct stents after ERCP, and develop effective clinical strategies for preventing pancreatitis after gallbladder-preserving stone extraction in gallstone patients.",[279],"Cholelithiasis Associated With Common Bile Duct Stones",[281,282,283,284],"Cholelithiasis with Concomitant Choledocholithiasis","Endoscopic Transpapillary Gallbladder-preserving Cholecystolithotomy","post-ERCP pancreatitis","Randomized Controlled Trial (RCT)","2026-05-14",{"date":287,"type":44},"2026-05-18",{"date":289,"type":44},"2025-12-01",{"date":291,"type":22},"2028-06",{"name":50,"class":51},{"id":294,"slug":295,"hasResults":12,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":300,"targetDuration":302,"studyType":62,"phases":4,"briefSummary":303,"conditions":304,"keywords":305,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":308,"startDateStruct":309,"completionDateStruct":310,"leadSponsor":312,"locationsCount":77},"100624702","treatment-outcomes-and-complications-of-three-therapeutic-approaches-for-concomitant-choledocholithiasis-and-cholecystolithiasis-100624702","NCT07413068","Treatment Outcomes and Complications of Three Therapeutic Approaches for Concomitant Choledocholithiasis and Cholecystolithiasis","Comparative Study of ERCP, ERCP Plus Laparoscopic Cholecystectomy, and Conservative Management in Patients With Concomitant Choledocholithiasis and Cholecystolithiasis.","Inclusion Criteria\n\n1. Patients over the age of 18 years;\n2. Ultrasound, MRCP, or other imaging examination findings (CT\u002FMRI) clearly indicate a diagnosis of cholelithiasis with concomitant choledocholithiasis;\n3. Patients with no history of gastrointestinal reconstruction surgery or cholecystectomy or previous biliary tract surgery (include history of ERCP);\n4. Patients with every gallbladder stone ≤1 cm in diameter or sludge-like stones;\n5. The morphology and size of the gallbladder are essentially normal and the thickness of the gallbladder wall is ≤3 mm;\n6. Voluntary provision of signed informed consent.\n\nExclusion Criteria\n\n1. Atrophic cholecystitis; porcelain gallbladder; suspect malignant tumor of the gallbladder; stenosis of the lower segment of the common bile duct; Mirrizzi syndrome;\n2. Unable to undergo endoscopic interventions for various reasons;\n3. Absolute surgical contraindications, including severe hepatic, renal, cardiac and pulmonary insufficiency, history of cerebral coma and allergy to anesthesia, etc;\n4. Presence of ectopic duodenal papilla or congenital pancreaticobiliary malformation;\n5. Patients with severe coagulopathy, defined as an International Normalized Ratio (INR) \\> 1.5 or patients with significant thrombocytopenia (platelet count \\\u003C 50 × 10⁹\u002FL);\n6. Pregnant women;",{"count":301,"type":22},300,"36 Months","Recruit patients with cholelithiasis with concomitant choledocholithiasis into the cohort, and assign them to undergo endoscopic transpapillary gallbladder-preserving cholecystolithotomy or ERCP plus laparoscopic cholecystectomy or conservative treatment based on patient preference. Collect clinical data and patient-reported outcomes regularly at baseline and during follow-up in the cohort. Assess the clinical safety of ERCP-GPC and LC by evaluating the clinical success rate of treatment as well as the incidence of short-term and long-term postoperative complications; investigate the efficacy differences among endoscopic transpapillary gallbladder-preserving cholecystolithotomy or ERCP plus laparoscopic cholecystectomy or conservative treatment in managing cholelithiasis with concomitant choledocholithiasis.",[279],[281,282,306,307],"ERCP plus Laparoscopic Cholecystectomy","Conservative treatment",{"date":287,"type":44},{"date":289,"type":44},{"date":311,"type":22},"2030-12",{"name":50,"class":51},{"id":314,"slug":315,"hasResults":12,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":12,"sex":17,"minAge":320,"maxAge":321,"enrollmentInfo":322,"targetDuration":4,"studyType":23,"phases":323,"briefSummary":325,"conditions":326,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":330,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":77},"100568243","phase-2-spironolactone-improved-children-with-gene-mutations-related-to-ncor-100568243","NCT06678685","Spironolactone Improved Children With Gene Mutations Related to NCOR","An Exploratory Study of Spironolactone Tablets for the Treatment of Children With Gene Mutations Related to NCOR","Inclusion Criteria:\n\n1. ADOS-2 diagnostic criteria for autistic children\n2. Patients with NCOR related gene mutation detected by whole exon test;\n3. Age: 3-10 years old;\n4. The subject and (or) guardian sign the informed consent, agreeing that the researcher will cooperate with the clinical trial process and collect clinical data and peripheral blood and urine samples;\n\nExclusion Criteria:\n\n1. have other pathogenic mutations (confidence higher than the NCOR related mutation);\n2. Boys over 10 years old;\n3. Allergic to spironolactone, used spironolactone one month before enrollment;\n4. Hyperkalemia, serum potassium concentration \\> 5.5mmol\u002FL;\n5. Renal insufficiency;\n6. Used related drugs one month before enrollment: potassium supplement, angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, digoxin, coletenamine, acetylsalicylic acid, abiraterone;\n7. Fever (body temperature above 37.3°);\n8. Clinically significant metabolic, hematological, liver, immune, urological, endocrine, neurological, pulmonary, psychiatric, skin, allergic, renal, or other major conditions in the determination of ASD that may affect the interpretation of study findings or patient safety.","3 Years","10 Years",{"count":241,"type":22},[114,324],"PHASE3","MECP2, a key transcriptional regulator, has been shown to interact with the NCOR1\u002F2 complex to modulate gene expression. Specifically, MECP2 recruits the NCOR complex to specific genomic loci, facilitating histone deacetylation and chromatin remodeling, which are essential for the proper regulation of genes involved in synaptic function and neuronal maturation. Disruptions in the MECP2-NCOR interaction have been implicated in neurodevelopmental disorders, including Rett syndrome and autism spectrum disorder (ASD), highlighting the collaborative role of MECP2 and the NCOR1\u002F2 complex in maintaining neuronal homeostasis.\n\nBuilding on this, NCOR1\u002F2 constitutes the NCOR complex,interacts with many different nuclear receptors to produce special physiological effects. The receptors further recruit epigenome-modifying enzymes that are involved in the transcription of multiple genes involved in neurotransmission and synaptic plasticity. Studies of mice with gene knockout and autistic with NCOR mutations have found that both exhibit clinical symptoms characteristic of ASD, such as deficits in social interaction, spatial learning, and impaired recognition memory. Further study revealed that the cause was the hyperexcitability of GABAergic neurons in the lateral hypothalamus (LH) due to the NCOR1\u002F2 defect, which impaired synaptic plasticity in the hippocampal CA3 region through the single synaptic LHGABA-CA3 neural projection, and thus exhibited learning\u002Fmemory impairment. Therefore, drugs that affect the NCOR receptor can improve learning\u002Fmemory impairment by affecting GABA neurons. Spironolactone is a widely used diuretic with good safety. Spironolactone is widely used in the treatment of hypertension, edema, and anti-androgen therapy in children. Spironolactone is currently under investigation as a potential treatment for children with NCOR gene mutations. Preclinical studies have demonstrated that spironolactone can ameliorate ASD-related symptoms in NCOR mutant mice, including reduced sensorimotor capacity, learning disability, and impaired working memory. Furthermore, the efficacy of related diuretics in the treatment of ASD has been demonstrated clinically. Therefore, spironolactone may represent a novel therapeutic target for patients with NCOR-related gene mutations in the future.",[327,328,329],"NCOR Gene Mutations","Spironolactone","ASD",{"date":287,"type":44},{"date":332,"type":44},"2024-10-30",{"date":334,"type":22},"2027-12-30",{"name":50,"class":51},{"id":337,"slug":338,"hasResults":12,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":342,"eligibilityCriteria":343,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":110,"enrollmentInfo":344,"targetDuration":4,"studyType":23,"phases":346,"briefSummary":347,"conditions":348,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":360},"100587721","phase-2-phase-ii-trial-of-iparomlimabtuvonralimab-ql1706--xelox-in-her2-negative-low-pd-l1-ggej-adenocarcinoma-100587721","NCT06932068","Phase II Trial of Iparomlimab\u002FTuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G\u002FGEJ Adenocarcinoma","Safety and Efficacy of Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for the Treatment of HER2-Negative, Low PD-L1 Expressing, Unresectable or Metastatic Gastric\u002FGastroesophageal Junction Adenocarcinoma: A Phase II Single-Arm Trial","SEARCH","Inclusion Criteria:\n\n1. Aged 18-75 years, gender is not limited;\n2. Pathologically confirmed locally advanced gastric or gastroesophageal junction adenocarcinoma that is inoperable or has distant metastasis;\n3. HER2-negative by immunohistochemistry (IHC);\n4. low PD-L1 expression status (CPS \\\u003C 5);\n5. Has at least 1 measurable lesion as determined by RECIST 1.1;\n6. No systematic treatment in the past, or the patient has received neoadjuvant\u002Fadjuvant chemotherapy, but the disease progresses or relapses more than 6 months after the end of treatment;\n7. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;\n8. Adequate organ function;\n9. The life expectancy is at least 3 months;\n10. Willing to join the study and signed an informed consent form (ICF) with good compliance and cooperation in follow-up.\n\nExclusion Criteria:\n\n1. Allergic to any trial drug and its excipients, or serious allergy history, or contraindication of the trial drug;\n2. Cardiovascular and cerebrovascular events that are not well controlled;\n3. Has received systematic treatment with Chinese patent medicine or immunomodulatory drugs (including thymosin, interferon, interleukin, except for local use for ascites control) before the first administration within 2 weeks;\n4. Have a history of interstitial lung disease, non-infectious pneumonia, pulmonary fibrosis, acute lung disease, or systemic disease with poor control (including but not limited to diabetes, hypertension, etc.);\n5. Have a history of active immune deficiency or autoimmune diseases, including HIV positive test, or have other acquired or congenital immune deficiency diseases, or have a history of organ transplantation or autoimmune diseases;\n6. Severe chronic or active infection requires systemic antibacterial, antifungal or antiviral treatment, including tuberculosis infection.Have a history of active tuberculosis infection ≥ 1 year before recruitment should also be excluded, unless proved has been completed appropriate treatment;\n7. Brain metastasis or leptomeningeal metastasis;\n8. Clinically significant pleural effusion, pericardial effusion or ascites should be drained for many times within 2 weeks before the first administration of the trial drug;\n9. Has a second clinically detectable primary malignant tumor at the time of recruitment, or there were other malignant tumors in the past 5 years (except for fully treated skin basal cell carcinoma or cervical carcinoma in situ);\n10. Any major surgery was performed ≤ 28 days before the first trial drug administration;\n11. History of allogeneic stem cell transplantation or organ transplantation;\n12. Duodenal ulcer, ulcerative colitis, intestinal obstruction and other gastrointestinal diseases at present; or other conditions that may cause gastrointestinal bleeding or perforation judged by the researchers; or history of intestinal perforation or fistula, but has not recovered after surgical treatment;\n13. Live vaccine was inoculated within 4 weeks (inclusive) before the first administration of the trial drug, not including seasonal influenza vaccines but intranasal vaccine.\n14. Has other factors that may lead to the forced termination of this trial according to the judgment of the investigator, such as other serious diseases (including psychological and mental diseases) requiring combined treatment, serious laboratory examination abnormalities, and family or social factors, which may affect the safety of the subject, or the collection of data and samples;\n15. Participating in other therapeutic clinical studies or using research instruments within 4 weeks before the first administration;\n16. Others conditions do not meet the inclusion according to the judgment of the investigator.",{"count":345,"type":22},77,[114],"This is single - arm study to explore the safety and efficacy of iparomlimab and tuvonralimab (QL1706) combined with chemotherapy for treating her2-negative, low PD-L1 expressing, unresectable or metastatic gastric\u002Fgastroesophageal junction adenocarcinoma",[349,350,351],"HER2 Negative","Low PD-L1 Expressing","Unresectable or Metastatic Gastric\u002FGastroesophageal Junction Adenocarcinoma","2026-05-02",{"date":354,"type":44},"2026-05-07",{"date":356,"type":44},"2025-03-26",{"date":358,"type":22},"2027-10-31",{"name":50,"class":51},29,{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":365,"acronym":4,"eligibilityCriteria":366,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":367,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":369,"conditions":370,"keywords":372,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":77},"100634713","an-artificial-intelligence-system-for-multimodal-multi-class-diagnosis-of-pancreatic-cystic-lesions-based-on-endoscopic-ultrasonography-100634713","NCT07543263","An Artificial Intelligence System for Multimodal, Multi-class Diagnosis of Pancreatic Cystic Lesions Based on Endoscopic Ultrasonography","Inclusion Criteria:\n\n\\- 1. Patients aged ≥18 years scheduled for EUS with suspected pancreatic cystic lesions based on clinical symptoms, medical history, laboratory tests or radiological examinations, and who agree to participate in the research and voluntarily sign the informed consent.\n\n2\\. Patients with no prior history of treatment for pancreatic lesions.\n\nExclusion Criteria:\n\n\\- 1. Patients with absolute contraindications to EUS examination. 2. Pregnancy or lactating. 3. Uncorrectable coagulopathy(PTT\\>50 seconds or INR\\>1.5) and\u002For uncorrectable thrombocytopenia(platelet count\\\u003C50×109\u002FL). 4. Upper gastrointestinal obstruction. 5. Patients who underwent surgical treatment or anatomical alterations of the pancreas due to lesions in other thoracic and\u002For abdominal organs, as well as patients with congenital anatomical abnormalities.\n\n6\\. Patients who have undergone biliary\u002Fpancreatic duct stent placement. 7. Patients who refuse to sign the informed consent.",{"count":368,"type":22},176,"The aim of this study is to develop and validate an artificial intelligence system named iEUS-PCL (intelligent endoscopic ultrasound system-pancreatic cystic lesions） for detecting and multimodal, multi-class diagnosing pancreatic cystic lesions (PCL) during endoscopic ultrasound (EUS) examination.",[371],"Pancreatic Cystic Lesion (PCL)",[373,374,375],"endoscopic ultrasound","pancreatic cystic lesion","machine learning","2026-04-23",{"date":378,"type":44},"2026-04-29",{"date":380,"type":22},"2026-04-20",{"date":382,"type":22},"2028-06-30",{"name":50,"class":51},{"id":385,"slug":386,"hasResults":12,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":4,"eligibilityCriteria":390,"healthyVolunteers":12,"sex":17,"minAge":391,"maxAge":110,"enrollmentInfo":392,"targetDuration":4,"studyType":23,"phases":394,"briefSummary":395,"conditions":396,"keywords":400,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":77},"100634991","high-frequency-repetitive-transcranial-magnetic-stimulation-for-cognitive-improvement-in-patients-with-post-stroke-cognitive-impairment-100634991","NCT07546877","High-Frequency Repetitive Transcranial Magnetic Stimulation for Cognitive Improvement in Patients With Post-Stroke Cognitive Impairment","Efficacy of High-Frequency Repetitive Transcranial Magnetic Stimulation in Patients With Post-Stroke Cognitive Impairment: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Meets the diagnostic criteria for stroke as stipulated in the \"Guidelines for the Prevention and Treatment of Stroke in China (2021 Edition)\", and the initial stroke diagnosis is confirmed by cranial CT or MRI examination, and is confirmed as the initial onset;\n2. The disease course is 1-12 months;\n3. Has cognitive impairment (MoCA \\\u003C 26 points, education years ≤ 12 years, add 1 point to the score result);\n4. Age 35-75 years old, gender not limited;\n5. Stable vital signs, no progressive neurological symptoms;\n6. No severe aphasia, visual or auditory impairment, and able to complete the research protocol;\n7. Not using antidepressant drugs simultaneously;\n8. If using cognitive-improving drugs (such as donepezil, memantine), it should last for at least 3 weeks or more, and no dose adjustment will be made during the enrollment period;\n9. Voluntarily participate and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Has a history of brain tumors, brain trauma, epilepsy or mental disorders;\n2. Had cognitive impairment before the stroke;\n3. Underwent craniotomy or had a skull defect;\n4. Had implanted metal or electronic devices (such as cardiac pacemakers, cochlear implants, deep brain stimulators, aneurysm clips, internal fixation devices after ventriculoperitoneal shunt surgery, etc.);\n5. Has other serious diseases that may affect the study;\n6. Pregnant women","35 Years",{"count":393,"type":22},40,[25],"To clarify the clinical efficacy of high-frequency rTMS on patients with post-stroke cognitive impairment, fNIRS and EEG techniques were used to observe the changes in brain functional activities of patients with post-stroke cognitive impairment after rTMS treatment, and to clarify the neuroregulatory effect of rTMS on patients with post-stroke cognitive impairment.",[397,398,399],"Post-Stroke Cognitive Impairment (PSCI)","Repetitive Transcranial Magnetic Stimulation (rTMS)","Stroke",[401,402],"randomized controlled trials","double blind","2026-04-21",{"date":376,"type":44},{"date":406,"type":22},"2026-04-01",{"date":408,"type":22},"2027-07-01",{"name":50,"class":51},{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":414,"acronym":4,"eligibilityCriteria":415,"healthyVolunteers":135,"sex":17,"minAge":320,"maxAge":416,"enrollmentInfo":417,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":419,"conditions":420,"keywords":423,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":430,"leadSponsor":432,"locationsCount":4},"100634260","a-case-control-observational-study-of-peripheral-blood-derived-ipsc-models-to-investigate-oligodendrocyte-lineage-development-in-children-with-williams-syndrome-and-healthy-controls-100634260","NCT07537374","A Case-Control Observational Study of Peripheral Blood-Derived iPSC Models to Investigate Oligodendrocyte Lineage Development in Children With Williams Syndrome and Healthy Controls","Inclusion Criteria:\n\n1. The clinical diagnosis is Williams syndrome.\n2. Child subjects;\n3. The guardian signs the informed consent form. If necessary, the subject himself\u002Fherself signs the informed consent or the informed consent with additional consent.\n4. Be capable of completing peripheral blood collection;\n\nExclusion Criteria:\n\n1. Cases of severe infection, severe hematological diseases or other conditions that make blood collection inappropriate;\n2. Recent receipt of special treatments that may significantly affect the state of peripheral blood cells;\n3. Insufficient sample volume or poor sample quality that does not meet the requirements for reprogramming experiments;\n4. Guardians' refusal to allow the samples to be used for iPSC establishment and subsequent research;\n5. Other circumstances judged by the researchers as not suitable for inclusion in this study.","12 Years",{"count":418,"type":22},6,"This study aims to collect peripheral blood samples from children with Williams syndrome (WS) and healthy children, establish a cell line of induced pluripotent stem cells (iPSCs) derived from the subjects, and further induce and differentiate them into neural progenitor cells (NPCs) and oligodendrocyte lineage cells for in vitro studies on the cellular and molecular mechanisms of WS-related neurodevelopmental abnormalities. Based on previous basic and pre-experimental results, the study focuses on the developmental transition of oligodendrocyte lineage from OPC to pre-OL, immature oligodendrocytes, and mature oligodendrocytes, and specifically evaluates the programs of myelin-related genes, differentiation trajectories, and abnormalities in related pathways such as GTF2I\u002FFZD9, ERK\u002FMAPK, and Wnt\u002Fβ-catenin. The study design is an independent donor case-control study, and it plans to include 3 children with WS and 3 healthy children. Each sample will be independently sequenced.",[421,422],"Williams Syndrome","Induced Pluripotent Stem Cell (Ips Cell)",[424,425],"Williams syndrome","induced pluripotent stem cell (ips cell)","2026-04-15",{"date":428,"type":44},"2026-04-17",{"date":406,"type":22},{"date":431,"type":22},"2027-01-01",{"name":50,"class":51},{"id":434,"slug":435,"hasResults":12,"nctId":436,"briefTitle":437,"officialTitle":438,"acronym":439,"eligibilityCriteria":440,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":441,"enrollmentInfo":442,"targetDuration":4,"studyType":23,"phases":444,"briefSummary":445,"conditions":446,"keywords":448,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":452,"startDateStruct":453,"completionDateStruct":455,"leadSponsor":456,"locationsCount":77},"100634258","phase-2-safety-and-efficacy-of-leucine-restricted-diet-combined-with-chemotherapy-and-immunotherapy-in-advanced-gastric-cancer-100634258","NCT07537348","Safety and Efficacy of Leucine-Restricted Diet Combined With Chemotherapy and Immunotherapy in Advanced Gastric Cancer","A Study on the Safety and Efficacy of Leucine-Restricted Diet in Gastric Cancer Patients Treated With Chemotherapy and Immunotherapy","LUCENT-GC-03","Inclusion Criteria:\n\n* Diagnosis and Treatment Plan: Patients with advanced gastric cancer with distant metastasis, confirmed by imaging modalities (such as CT or PET-CT) and clinical pathological data, who are indicated for combined chemotherapy and immunotherapy.\n* Demographics: Aged 18 to 70 years, regardless of gender.\n* Dietary Capability: Capable of oral intake or receiving liquid diet via nasogastric tube.\n* Consent: Willing to participate in this study and have signed the Informed Consent Form (ICF).\n* Exclusion of Other Malignancies: No concurrent primary malignant tumors other than gastric cancer.\n\nExclusion Criteria:\n\n* Cognitive or Psychiatric Impairment: Cognitive dysfunction or psychiatric disorders that prevent the patient from understanding the study content or providing informed consent.\n* Diabetes Mellitus: Diagnosis of Type 1 or Type 2 diabetes mellitus.\n* Gastrointestinal Conditions: Presence of severe diarrhea, intractable vomiting, severe malabsorption syndrome, paralytic or mechanical intestinal obstruction, or active gastrointestinal bleeding.\n* Allergy：Known hypersensitivity or allergy to any of the main components of the leucine-deficient nutritional powder.\n* Concomitant Supplements: Current use of other nutritional supplements that may potentially confound the study results or affect efficacy evaluation.\n* Treatment Tolerance: Inability to tolerate combined chemotherapy and immunotherapy, or occurrence of severe gastrointestinal adverse events following such treatment.","70 Years",{"count":443,"type":22},73,[114],"Based on existing literature, we posit that a leucine-restricted diet is safe and well-tolerated in patients with advanced gastric cancer receiving combined chemotherapy and immunotherapy. Patients adhering to this dietary regimen exhibit a significant reduction in serum leucine concentrations, with no notable impact on the serum levels of other amino acids. Furthermore, leucine restriction promotes the activation of immune cells within the tumor microenvironment. When applied in conjunction with chemotherapy and immunotherapy for advanced gastric cancer, this approach demonstrates synergistic anti-tumor efficacy. It is expected to enhance tumor response rates , improve the 1-year survival rate, prolong overall survival (OS), and ultimately optimize patient prognosis.",[447],"Advanced Gastric Cancer",[447,449,450,451],"Leucine-Restricted Diet","Chemotherapy","Immunotherapy",{"date":428,"type":44},{"date":454,"type":44},"2026-01-01",{"date":213,"type":22},{"name":50,"class":51},{"id":458,"slug":459,"hasResults":12,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":463,"eligibilityCriteria":464,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":441,"enrollmentInfo":465,"targetDuration":4,"studyType":23,"phases":467,"briefSummary":468,"conditions":469,"keywords":472,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":477,"startDateStruct":478,"completionDateStruct":479,"leadSponsor":481,"locationsCount":77},"100634259","phase-2-safety-and-efficacy-of-leucine-restricted-diet-combined-with-neoadjuvant-chemotherapy-and-immunotherapy-in-gastric-cancer-100634259","NCT07537361","Safety and Efficacy of Leucine-Restricted Diet Combined With Neoadjuvant Chemotherapy and Immunotherapy in Gastric Cancer","A Study on the Safety and Efficacy of Leucine-Restricted Diet in Gastric Cancer Patients Treated With Neoadjuvant Chemotherapy and Immunotherapy","LUCENT-GC-02","Inclusion Criteria:\n\n* Pathological Confirmation: Histologically confirmed locally advanced gastric cancer.\n* Demographics: Aged 18 to 70 years, inclusive, regardless of gender.\n* Dietary Capability: Capable of oral intake or receiving a liquid diet via nasogastric tube.\n* Consent: Willing to participate in the study and have signed the Written Informed Consent Form (ICF).\n* Staging and Treatment Indication: No evidence of distant metastasis on imaging examinations (such as CT or PET-CT), with a clinical stage of locally advanced gastric cancer, indicating the need for neoadjuvant chemo-immunotherapy prior to surgery.\n* Exclusion of Other Malignancies: No concurrent primary malignant tumors other than gastric cancer.\n\nExclusion Criteria:\n\n* Cognitive or Psychiatric Impairment: Cognitive dysfunction or psychiatric disorders severe enough to prevent the patient from understanding the study content or providing informed consent.\n* Diabetes Mellitus: Diagnosis of Type 1 or Type 2 diabetes mellitus.\n* Gastrointestinal Conditions: Presence of severe diarrhea, intractable vomiting, severe malabsorption syndrome, paralytic or mechanical intestinal obstruction, or active gastrointestinal bleeding.\n* Allergy\u002FHypersensitivity: Known hypersensitivity or allergy to any of the main components of the leucine-deficient nutritional powder.\n* Concomitant Supplements: Current use of other nutritional supplements that may potentially confound the study results or affect the evaluation of efficacy.\n* Treatment Tolerance: Inability to tolerate neoadjuvant chemo-immunotherapy, or occurrence of severe gastrointestinal adverse events following such treatment.\n* Pathological Diagnosis: Postoperative pathological diagnosis confirming non-primary gastric cancer (e.g., metastatic tumors from other origins).",{"count":466,"type":22},108,[114],"Consistent with previous literature, the investigators postulate that a leucine-restricted diet is safe and well-tolerated in gastric cancer patients receiving neoadjuvant chemo-immunotherapy. Furthermore, the investigators propose that this dietary regimen promotes the activation of immune cells within the tumor microenvironment (TME). When combined with neoadjuvant chemo-immunotherapy, it demonstrates synergistic anti-tumor efficacy, thereby improving patient prognosis.",[470,471],"Gastric Cancer","Leucine-restricted Diet",[473,474,475,476],"gastric cancer","leucine-restricted diet","Neoadjuvant Therapy","immunotherapy",{"date":428,"type":44},{"date":454,"type":44},{"date":480,"type":22},"2027-08-31",{"name":50,"class":51},{"id":483,"slug":484,"hasResults":12,"nctId":485,"briefTitle":486,"officialTitle":487,"acronym":488,"eligibilityCriteria":489,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":490,"targetDuration":4,"studyType":23,"phases":491,"briefSummary":492,"conditions":493,"keywords":496,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":501,"startDateStruct":502,"completionDateStruct":503,"leadSponsor":505,"locationsCount":77},"100631841","acupuncture-for-postoperative-gastric-emptying-delay-100631841","NCT07505927","Acupuncture for Postoperative Gastric Emptying Delay","Acupuncture for POstoperative Gastric Emptying dElay (APOGEE): A Multicenter Randomized Controlled Trial","APOGEE","Inclusion Criteria:\n\n1. Aged 18-80 years, regardless of sex.\n2. Patients who have undergone partial gastrectomy.\n3. Patients presenting with postoperative gastroparesis symptoms, confirmed by imaging or gastric emptying scintigraphy, and clinically diagnosed with gastroparesis.\n4. No severe cardiac, hepatic, renal, or coagulation dysfunction.\n5. No participation in other interventional clinical trials within the past month.\n6. Able to provide written informed consent and comply with the treatment and follow-up procedures.\n\nExclusion Criteria:\n\n1. Patients with severe cardiovascular or cerebrovascular diseases, hepatic or renal failure, or coagulation disorders.\n2. Patients who develop serious postoperative complications after partial gastrectomy, such as anastomotic leakage, gastrointestinal bleeding, or severe infections, or conditions that may affect the assessment of gastric motility, such as ascites or intestinal obstruction.\n3. Patients with a known allergy to acupuncture or with skin damage, infection, or severe scarring at the needle insertion sites that would prevent proper acupoint selection or needling.\n4. Patients with diagnosed psychiatric disorders, cognitive impairment, or those unable to cooperate with treatment procedures, symptom assessment, or follow-up.\n5. Patients who have used medications that may significantly affect gastric motility within the past week and cannot discontinue their use.\n6. Pregnant or breastfeeding women, or individuals with other special physiological conditions that may make them unsuitable for participation in acupuncture research.",{"count":368,"type":22},[25],"This multicenter clinical trial, conducted at Qilu Hospital of Shandong University and collaborating institutions, prospectively assesses the efficacy and safety of acupuncture for postoperative delayed gastric emptying. Eligible participants will be prospectively enrolled and randomized into different groups per the study protocol. The primary endpoint is the reduction in the duration of delayed gastric emptying, while secondary endpoints include the complete resolution of cardinal gastroparetic symptoms, such as abdominal distension, nausea, and vomiting. All study procedures adhere to the ethical standards outlined in the approved protocol.",[494,495],"Gastroparesis Postoperative","Delayed Gastric Emptying Following Procedure",[497,498,499,500],"Gastroparesis","Acupuncture","Delayed Gastric Emptying","partial gastrectomy",{"date":380,"type":44},{"date":406,"type":22},{"date":504,"type":22},"2028-06-01",{"name":50,"class":51},{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":4,"eligibilityCriteria":512,"healthyVolunteers":12,"sex":17,"minAge":513,"maxAge":4,"enrollmentInfo":514,"targetDuration":4,"studyType":23,"phases":515,"briefSummary":516,"conditions":517,"keywords":519,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":523,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":528,"locationsCount":77},"100631842","bilateral-comparison-of-unilateral-sacral-neuromodulation-test-stimulation-in-the-treatment-of-neurogenic-bladder-100631842","NCT07505940","Bilateral Comparison of Unilateral Sacral Neuromodulation Test Stimulation in the Treatment of Neurogenic Bladder","Bilateral Comparison of Unilateral Sacral Neuromodulation Test Stimulation in the Treatment of Neurogenic Bladder: A Prospective, Randomized Controlled Study","Inclusion Criteria:\n\n1. age ≥16 years old;\n2. The nerve injury was incomplete injury below grade B, which was diagnosed as neurogenic bladder;\n3. Overactive bladder with and\u002For low compliance bladder (overactive bladder was defined as detrusor contraction during filling, increased intravesical pressure, and early emptying before maximum bladder capacity was reached; Low compliance bladder was defined as loss of the ability to relax during bladder filling, progressive increase of bladder pressure, early emptying of bladder pressure increased, ≤20ml\u002FcmH20).\n4. Intermittent catheterization (CIC) can be performed by themselves or CIC can be performed by nursing staff;\n5. the patient's physical condition is stable and can be discharged for treatment;\n6. Participants voluntarily participated in the clinical study, and they provided written informed consent before the study began\n\nExclusion Criteria:\n\n1. Patients can not perform intermittent catheterization (CIC) by themselves and there is no nursing staff to perform CIC;\n2. a history of progressive neurological disorders;\n3. abnormal autonomic reflexes;\n4. pregnant, lactating women, women of childbearing age who plan to become pregnant during the study period, or who do not use safe contraception;\n5. patients with mental and cognitive impairment who are unable to cooperate with surgery and programming;\n6. patients have coagulopathy or need anticoagulant therapy and cannot stop the treatment;\n7. any serious complications or illnesses that may prevent the patient from participating in or increase the patient's risk of undergoing a surgical procedure;\n8. Participants who participated in other clinical trials within 3 months before screening, which may have affected the study results;\n9. other conditions considered by the investigator to be inappropriate for study participation.","16 Years",{"count":360,"type":22},[25],"Neurogenic bladder (NB) is a general term for a series of lower urinary tract symptoms and complications caused by bladder and\u002For urethral dysfunction caused by nervous system lesions. Neurogenic bladder brings physical and psychological pain to patients, affects interpersonal relationships, and seriously reduces the quality of life of patients.\n\nSacral neuromodulation (SNM) is an effective method for the treatment of refractory lower urinary tract dysfunction. A previous study analyzed bilateral peripheral nerve evaluation (PNE) in 62 patients with idiopathic and neurogenic bladder. The results of this clinical study showed that 51.6% of the patients (32 cases) achieved symptomatic improvement. Although a prospective controlled study was not performed, the authors suggest that bilateral treatment may improve symptoms in patients with idiopathic and neurogenic bladder compared with unilateral treatment, compared with remission rates in other previous clinical studies.\n\nAt present, there are few reports on the application of bilateral sacral neuromodulation stimulation in the treatment of voiding dysfunction, and it is still controversial whether the efficacy of bilateral stimulation is better than unilateral stimulation. Therefore, we intend to conduct a prospective, randomized controlled trial to evaluate the efficacy and safety of bilateral sacral neuromodulation test stimulation in the treatment of neurogenic lower urinary tract dysfunction.",[518],"Neurogenic Bladder",[520,521],"neurogenic bladder","sacral neuromodulation","2026-03-29",{"date":406,"type":44},{"date":525,"type":22},"2026-03-31",{"date":527,"type":22},"2027-03-01",{"name":50,"class":51},{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":533,"acronym":534,"eligibilityCriteria":535,"healthyVolunteers":135,"sex":17,"minAge":320,"maxAge":416,"enrollmentInfo":536,"targetDuration":538,"studyType":62,"phases":4,"briefSummary":539,"conditions":540,"keywords":542,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":546,"startDateStruct":548,"completionDateStruct":549,"leadSponsor":551,"locationsCount":77},"100632145","research-on-the-molecular-mechanism-of-cognitive-differences-between-williams-syndrome-and-autism-spectrum-disorder-100632145","NCT07509879","Research on the Molecular Mechanism of Cognitive Differences Between Williams Syndrome and Autism Spectrum Disorder","WS and ASD","Participants for Williams Syndrome Study\n\nInclusion criteria must all be met:\n\n1. Age 3-12 years old.\n2. Clinically diagnosed and confirmed by fluorescence in situ hybridization (FISH) test, with a typical microdeletion of approximately 1.55 Mb in the chromosome 7q11.23 region.\n3. Their legal guardians fully understand the study content and voluntarily sign the informed consent form, agreeing for the study participants to undergo blood sampling and genetic testing.\n\nParticipants for Autism Spectrum Disorder Study\n\nInclusion criteria must all be met:\n\n1. Age 3-12 years old.\n2. Clinically diagnosed according to the second edition of the Autism Diagnostic Observation Schedule (ADOS-2) criteria.\n3. Their legal guardians fully understand the study content and voluntarily sign the informed consent form, agreeing for the study participants to undergo blood sampling and genetic testing.\n\nParticipants for Healthy Children Study\n\nInclusion criteria must all be met:\n\n1. Age 3-12 years old, with gender as close as possible to the participants in the above two groups.\n2. No history of neurodevelopmental disorders, mental illnesses or major neurological diseases.\n3. Their legal guardians fully understand the study content and voluntarily sign the informed consent form, agreeing for the study participants to undergo blood sampling and genetic testing.\n\nCommon Exclusion Criteria for All Study Participants\n\nAny of the following conditions must be met to be excluded from the study:\n\n1. Specific medical conditions:\n2. For the Williams Syndrome group: Known or suspected presence of other pathogenic gene mutations\u002Fsyndromes other than the 7q11.23 microdeletion.\n3. For the Autism Spectrum Disorder group: Co-occurring other clearly diagnosed neurodevelopmental disorders (such as Rett syndrome, fragile X syndrome, etc.).\n4. Brain structural abnormalities: According to recent cranial MRI and interpretation by neuro-radiology experts, significant brain structural lesions are found (for the patient group, referring to lesions unrelated to Williams Syndrome or autism; for the healthy group, referring to any clinically significant abnormalities).\n5. Major systemic diseases: Presence of diseases with clinical significance as judged by the researchers, which may: affect the interpretation of study results, or endanger the safety of the study participants.",{"count":537,"type":22},75,"1 Month","Williams Syndrome (WS) is a rare neurodevelopmental disorder, usually caused by microdeletions of approximately 26 genes in the long arm (7q11.23) region of chromosome 7. Children with this syndrome often exhibit distinctive facial features, mild to moderate intellectual disability, impaired spatial cognition, pronounced social extraversion, and relatively reserved language-expression characteristics. Although individuals with WS often demonstrate strong social interest and prosocial behaviors, significant deficiencies in abstract thinking, executive function, and visuospatial ability are frequently observed. At present, treatment for WS mainly focuses on behavioral intervention and educational rehabilitation, and clear molecular or pharmacological treatment methods remain limited. Due to the \"opposite but related\" social-cognitive profile observed in comparison with autism spectrum disorder, in-depth exploration of neural and molecular mechanisms underlying these differences has substantial scientific significance for understanding the biological basis of social-cognitive impairment.",[421,541],"Autism Disorder",[421,543,544,545],"Autism Spectrum Disorder","Neuroimaging","Genetics",{"date":547,"type":44},"2026-04-03",{"date":406,"type":22},{"date":550,"type":22},"2026-12-01",{"name":50,"class":51},{"id":553,"slug":554,"hasResults":12,"nctId":555,"briefTitle":556,"officialTitle":557,"acronym":4,"eligibilityCriteria":558,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":559,"targetDuration":4,"studyType":23,"phases":561,"briefSummary":562,"conditions":563,"keywords":564,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":570,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":576,"locationsCount":77},"100570194","virtual-reality-task-oriented-training-on-upper-limb-function-in-stroke-patients-100570194","NCT06704074","Virtual Reality Task Oriented Training on Upper Limb Function in Stroke Patients","Effectiveness of Real Home Settings Via Virtual Reality Task Oriented Training on Upper Llimb Function in Patients With Stroke: A Multicenter, Randomized Controlled Clinical Trial.","Inclusion Criteria:\n\n-1. Ischemic or hemorrhagic stroke was diagnosed based on the history, symptoms, and signs combined with CT or MRI imaging; 2. First stroke, onset time from 1 to 6 months, age ≥ 18 - 80 years ; 3. Hemiplegia, Brunnstrom stage ≥ Ⅱ - Ⅴ, modified Ashworth grade \\\u003C 4; 4. Able to maintain sitting balance (with no or only minimal assistance) for at least 30 minutes to facilitate assessment and training; 5. No significant unilateral neglect (confirmed by tests such as the Schenkenberg Line Bisection Test); visual or corrected vision and hearing must be sufficient to meet the requirements for VR training and to understand instructions.\n\n6.Patients or their family members signed informed consent to participate in the experiment.\n\nExclusion Criteria:\n\n* 1\\. Previous history of stroke, traumatic or non-vascular encephalopathy; 2. MOCA ≤ 17, and no sensory aphasia. 3. Skull defect or allogeneic repair; 4. combined with other neurological and mental diseases; 5. Previous diseases that may cause upper limb motor\u002Fsensory dysfunction, such as neck tumor or radiotherapy and chemotherapy history, cervical spondylosis, cervical spine or upper limb fracture history, traumatic brachial plexus injury history, arthritis, diabetes mellitus, myasthenia gravis, multiple sclerosis, etc.\n\n  6\\. Accompanied by obvious vertigo or dizziness symptoms or related diseases (such as motion sickness, Meniere's syndrome, otolithiasis, etc.); 6. Accompanied by obvious pain; 7. Significant pain in the affected upper limb or shoulder at rest or during activity (VAS ≥ 4 ) 8. Evidence of ataxia and cerebellar or brainstem lesions according to the NIHSS; 9. Ongoing participation in other clinical investigators; 10. Unstable condition, refusal to sign the informed consent, and unwillingness to cooperate with the examination and treatment.",{"count":560,"type":22},86,[25],"Stroke rank second among the top causes of death, affecting millions of people in the worldwide. It has been reported that hemiplegia is the most common sequelae after stroke, accounting for about 50%-70% of all sequelae of the disease. About 75% of stroke patients are accompanied by different degrees of upper limb dysfunction, which seriously affects the activities of daily life and cause serious physical and mental burden to patients and their families. Early recovery of upper limb motor function is a great significance for the overall recovery of stroke patients. Task-oriented training (TOT) is reported to improve the motor coordination and ADL. However, lack varies of tasks limited the treatment ability for patients with stroke hemiplegia during hospital admission. Virtual reality (VR) offers advantages of providing virtual scenes that is difficult in the real world, such as the scene of garden, camara, and plaza etc. And the familiar circumstances for patients may have the potential to increase the motivation of rehabilitation training, and improve the efficacy of occupational therapy (OT).\n\nThe goal of this study is to observe the effectiveness of real home settings via virtual reality assisted TOT on upper limb function in patients with stroke. Functional near-infrared spectroscopy (fNIRS) and electroencephalography (EEG) were used to observe the changes in brain function under VR-TOT training.\n\nWe intended to recruit 120 participants, and allocate to three groups: VR-TOT, TOT, and traditional OT. Each of them completed the Fugl-Meyer-UE, Wolf motor function test (WMFT), hand gripping power, modified Ashworth、Purdue Pegboard test （PPT）、modified Barthel index (MBI)、mini mental state examination (MMSE)、NIH stroke scale (NIHSS)、Virtual reality sickness questionnaire (VRSQ), Intrinsic Motivation Inventory Inventory (IMI), satisfaction VAS, body representation, sense of ownership, Proprioceptive Drift scale before and after the treatment. Additionally, we conducted fNIRS and EEG at baseline and during the follow up to understand the changes in brain function.",[399],[565,566,567,568,569],"stroke","rehabilitation","Task-oriented training (TOT)","virtual reality (VR)","upper limb dysfunction",{"date":571,"type":44},"2026-04-02",{"date":573,"type":22},"2026-04-05",{"date":575,"type":22},"2026-11-30",{"name":50,"class":51},{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":4,"eligibilityCriteria":583,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":584,"targetDuration":4,"studyType":23,"phases":586,"briefSummary":587,"conditions":588,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":592,"lastUpdatePostDateStruct":593,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":599,"locationsCount":77},"100631450","fasting-mimicking-diet-combined-with-io-tki-combination-therapy-in-patients-with-metastatic-renal-cell-carcinoma-100631450","NCT07500831","Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma","Fasting-Mimicking Diet Combined With Toripalimab Plus Axitinib for Metastatic or Unresectable Renal Cell Carcinoma: A Single-Arm, Open-Label, Single-Center Clinical Trial","Inclusion Criteria:\n\n1. Subjects voluntarily participate in the study and sign the informed consent form.\n2. Age ≥ 18 years at the time of signing the informed consent form; males or females are eligible.\n3. Pathologically confirmed advanced renal cell carcinoma (metastatic or unresectable) with predominant clear cell histology.\n4. No prior systemic anti-tumor therapy (except for cytokine therapy).\n5. At least one measurable target lesion according to RECIST v1.1 criteria (confirmed by CT or MRI).\n6. Body mass index (BMI) ≥ 20 kg\u002Fm².\n7. IMDC intermediate- or poor-risk group.\n8. Willing and able to comply with the fasting-mimicking diet (FMD)protocol,scheduled visits, treatment plan, laboratory tests, and other study procedures.\n9. Able to maintain daily contact with the investigator (via telephone or email) to communicate key clinical information, including daily body weight, blood pressure, health status, and adverse events during the 5-day FMD period.\n10. Low nutritional risk according to the Nutritional Risk Screening (NRS) tool.\n11. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n12. Adequate organ function within 7 days prior to the first dose of study drug (no blood products, hematopoietic growth factors, leukocyte- or platelet-stimulating agents allowed in the 7 days prior to laboratory testing):\n\n    Absolute neutrophil count ≥ 1.5 × 10⁹\u002FL Platelets ≥ 100 × 10⁹\u002FL Hemoglobin ≥ 90 g\u002FL Serum albumin ≥ 30 g\u002FL AST and ALT ≤ 2.5 × upper limit of normal (ULN); if liver metastases are present, AST and ALT ≤ 5 × ULN Total bilirubin ≤ 1.5 × ULN (≤ 3 × ULN allowed for subjects with Gilbert syndrome) Serum creatinine ≤ 1.5 × ULN; if \\> 1.5 × ULN, creatinine clearance (CLcr) calculated by Cockcroft-Gault formula must be ≥ 50 mL\u002Fmin Left ventricular ejection fraction (LVEF) \\> 50% Proteinuria \\\u003C 2+ (if ≥ 2+, 24-hour urine protein quantification must be \\\u003C 1 g) International normalized ratio (INR) ≤ 1.5 × ULN or prothrombin time (PT) prolongation ≤ 1.5 × ULN; activated partial thromboplastin time (APTT) ≤ 1.5 × ULN\n13. No plans for pregnancy during the study period.\n\nExclusion Criteria:\n\n1. Prior receipt of any systemic anti-tumor therapy for renal cell carcinoma (RCC), including systemic chemotherapy, anti-angiogenic therapy, molecular targeted therapy, immunotherapy containing anti-CTLA-4, anti-PD-1\u002FPD-L1 monoclonal antibodies, and immune checkpoint agonist antibodies (e.g., anti-ICOS, anti-CD40, anti-CD137, anti-GITR, or anti-OX40 antibodies).\n2. Unintentional weight loss ≥5% within the past 3 months, unless the patient has BMI \\>22 kg\u002Fm² and weight loss at study entry is \\\u003C10%; or unintentional weight loss ≥10% within the past 3 months, unless the patient has BMI \\>25 kg\u002Fm² and weight loss at study entry is \\\u003C15% (in both cases, body weight must have been stable for at least 1 month prior to study entry).\n3. Body mass index (BMI) \\\u003C20 kg\u002Fm².\n4. Moderate or high nutritional risk according to the Nutritional Risk Screening (NRS) assessment.\n5. Severe food allergy that prevents the subject from consuming the foods required for the fasting-mimicking diet (FMD).\n6. Symptomatic central nervous system (CNS) metastases, leptomeningeal metastases, or spinal cord compression due to metastases prior to the first dose of study treatment. Exception: Patients with symptomatic CNS metastases who have received treatment and are stable for ≥4 weeks (stable defined as no radiographic progression and resolution of metastasis-related symptoms) and have discontinued systemic corticosteroids (any dose), anticonvulsants, and mannitol for \\>2 weeks may be enrolled.\n7. History of other malignancies within 5 years prior to signing the informed consent form (except for cured basal cell skin carcinoma, papillary thyroid carcinoma, etc.).\n8. Active autoimmune disease requiring systemic treatment (e.g., corticosteroids or immunosuppressants) within the past 2 years prior to the first dose of the combination therapy.\n9. Any serious concomitant disease, as judged by the investigator, that may endanger the subject's safety or interfere with the subject's ability to complete the study.\n10. Receiving long-term systemic corticosteroid therapy (daily dose \\>10 mg prednisone equivalent) within 7 days prior to the first dose of the combination therapy.\n11. Any of the following cardiovascular diseases:\n\n    Acute myocardial infarction within 6 months prior to the first dose of the combination therapy.\n\n    History of and\u002For current New York Heart Association (NYHA) Class III or IV heart failure.\n\n    Poorly controlled cardiovascular disease, including angina, pulmonary hypertension, or severe cardiac rhythm or conduction abnormalities.\n\n    Mean QT interval corrected by Fridericia's formula (QTcF) \\>450 ms (male) or \\>470 ms (female) on 12-lead electrocardiogram (ECG) prior to the first dose of the combination therapy.\n12. Known history of substance abuse of psychotropic medications, alcohol abuse, or drug abuse; or history of definite neurological or psychiatric disorders, including epilepsy, dementia, or hepatic encephalopathy.\n13. Participation in another clinical study and receipt of other investigational therapy within 4 weeks prior to the first dose of the combination therapy.\n14. Major surgery within 4 weeks prior to the first dose of the combination therapy (adequate wound healing after major surgery must be clinically assessed).\n15. Arteriovenous thromboembolic events within 6 months prior to the first dose of the combination therapy, including cerebrovascular accident, history of stroke or transient ischemic attack, pulmonary embolism, deep vein thrombosis, or other serious thromboembolic events.\n16. Any patient, as judged by the investigator, who may increase the risk associated with the study, interfere with the interpretation of study results, or is deemed unsuitable for enrollment by the investigator and\u002For sponsor.",{"count":585,"type":22},43,[25],"This study is testing whether adding a 5-day fasting-mimicking diet (FMD) can help people with advanced kidney cancer when given together with standard first-line cancer medicines.",[589,590,591],"Carcinoma, Renal Cell","Metastatic Renal Cell Carcinoma","Advanced Renal Cell Carcinoma","2026-03-24",{"date":594,"type":44},"2026-03-30",{"date":596,"type":22},"2026-04",{"date":598,"type":22},"2029-04",{"name":50,"class":51},{"id":601,"slug":602,"hasResults":12,"nctId":603,"briefTitle":604,"officialTitle":605,"acronym":4,"eligibilityCriteria":606,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":607,"targetDuration":4,"studyType":23,"phases":609,"briefSummary":610,"conditions":611,"keywords":614,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":617,"lastUpdatePostDateStruct":618,"startDateStruct":620,"completionDateStruct":621,"leadSponsor":623,"locationsCount":4},"100631012","the-improvement-effect-of-real-time-artificial-intelligence-assisted-identification-of-bleeding-points-on-hemostasis-efficiency-in-endoscopic-submucosal-dissection-100631012","NCT07495137","The Improvement Effect of Real-time Artificial Intelligence Assisted Identification of Bleeding Points on Hemostasis Efficiency in Endoscopic Submucosal Dissection","The Improvement Effect of Real-time Artificial Intelligence Assisted Identification of Bleeding Points on Hemostasis Efficiency in Endoscopic Submucosal Dissection (ESD): a Multicenter, Randomized Controlled Trial","Inclusion Criteria\n\n1. Aged 18-80 years;\n2. Lesions meet the indications for ESD treatment of the esophagus, stomach, or colorectum according to relevant guidelines;\n3. Anticoagulant drugs have been suspended according to relevant guidelines;\n4. Patients with American Society of Anesthesiologists (ASA) classification Grade I or II;\n5. Patients who voluntarily sign the informed consent form.\n\nExclusion Criteria\n\n1. Patients with severe cardiopulmonary diseases, coagulation dysfunction or other severe comorbidities that may increase surgical risks;\n2. Patients undergoing dialysis treatment;\n3. Pregnant or lactating women;\n4. Deemed unsuitable for participation in this study by the principal investigator or other researchers.",{"count":608,"type":22},160,[25],"The goal of this clinical trial is to learn if an artificial intelligence (AI) system that identifies bleeding points in real time can help stop bleeding faster during endoscopic submucosal dissection (ESD) - a minimally invasive surgery for early digestive tract cancer or precancerous lesions. It will also learn about the AI system's effect on surgery-related problems (like perforation or delayed bleeding) and total surgery time.\n\nThe main questions it aims to answer are:\n\n1. Does the AI system shorten the time it takes to stop each bleed during ESD?\n2. How does the AI system affect the rate of surgery-related problems and total surgery time?\n\nResearchers will compare two groups to see if the AI system improves hemostasis efficiency:\n\n1. AI group: During ESD, the AI system will real-time spot and mark bleeding points. Doctors will use these marks to stop bleeding.\n2. Control group: Doctors will use the same equipment but without the AI system - they will find and stop bleeding using their own experience.\n\nParticipants will:\n\n1. Have ESD surgery for esophageal, stomach, or colorectal lesions that need this treatment;\n2. Be randomly assigned to either the AI group or the control group;\n3. Attend follow-up checks in 14 days after surgery to check for complications;\n4. Have their surgery videos reviewed by experts to record hemostasis time and total surgery time.",[612,613],"Endoscopic Submucosal Dissection","Endoscopic Submucosal Dissection (ESD)",[615,616],"Endoscopic submucosal dissection","Artificial intelligence","2026-03-22",{"date":619,"type":44},"2026-03-27",{"date":525,"type":22},{"date":622,"type":22},"2027-12-31",{"name":50,"class":51},""]